InnoCan Pharma (HAM:IP40) Tariff Resilience Score: 5/10 (As of Jul. 01, 2026)


HAM:IP40 InnoCan Pharma Corp HAM:IP40
59 GF Score
Price €1.34
GF Value €9.22
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is InnoCan Pharma Tariff Resilience Score?

InnoCan Pharma HAM:IP40 -5.32% 59 Tariff Resilience Score is 5 as of Jul. 01, 2026. GuruFocus rates HAM:IP40 with a GF Score™ of 59/100 and a GF Value™ of €9.22 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 2,047 Consumer Packaged Goods companies, InnoCan Pharma ranks better than 94.24% on this metric.

InnoCan Pharma has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

InnoCan Pharma has InnoCan Pharma's global supply chain and reliance on international markets for sales expose it to tariff risks. The company has limited pricing power but can explore alternative suppliers. The pharmaceutical industry may have some tariff exemptions, providing moderate resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes InnoCan Pharma might have Average Resilient.

InnoCan Pharma  (HAM:IP40) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

InnoCan Pharma Tariff Resilience Score Related Terms

HAM:IP40 vs PG, CL, KVUE: Tariff Resilience Score Comparison

For the Household & Personal Products subindustry, InnoCan Pharma's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InnoCan Pharma Tariff Resilience Score vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where InnoCan Pharma's Tariff Resilience Score falls into.


HAM:IP40
59GF Score
InnoCan Pharma Corp HAM:IP40
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
InnoCan Pharma (HAM:IP40) has a Tariff Resilience Score of 5 as of Jul. 01, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, InnoCan Pharma ranks #118 out of 2047 companies in the Consumer Packaged Goods industry, placing it in the top 5.8%.
Is InnoCan Pharma's Tariff Resilience Score too high?
InnoCan Pharma's current Tariff Resilience Score is 5. Based on the distribution chart, InnoCan Pharma ranks #118 out of 2047 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, InnoCan Pharma has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Tariff Resilience Score compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, InnoCan Pharma ranks #118 out of 2047 companies for Tariff Resilience Score. This places InnoCan Pharma in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Consumer Packaged Goods company?
A good Tariff Resilience Score depends on the Consumer Packaged Goods industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. InnoCan Pharma's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (HAM:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €9.22, compared to a current price of €1.34 — trading 85.5% below its estimated fair value. The current Tariff Resilience Score is 5. InnoCan Pharma's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For InnoCan Pharma (HAM:IP40), the current Tariff Resilience Score is 5 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InnoCan Pharma (HAM:IP40) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued. The current stock price of €1.34 is trading 85.5% below its estimated GF Value™ of €9.22. GuruFocus considers InnoCan Pharma to be Possible Value Trap.

Key valuation signals for HAM:IP40:

  • Tariff Resilience Score: 5
  • GF Value™: €9.22 vs. price of €1.34 (85.5% below fair value)
  • GF Score™: 59/100 with 2 warning signs

No single metric tells the full story. See the HAM:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InnoCan Pharma Business Description

Other Exchanges INNPF:USAINNO:Canada
Address 1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
59GF Score

Get the complete analysis for HAM:IP40

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.34
Price
€9.22
GF Value